Umirolimus: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Umirolimus == | |||
[[File:Umirolimus.svg|thumb|right|Chemical structure of Umirolimus]] | |||
'''Umirolimus''' is a [[pharmacological]] agent that belongs to the class of [[immunosuppressive drugs]]. It is primarily used in the field of [[medicine]] to prevent [[organ transplant]] rejection. Umirolimus is a derivative of [[sirolimus]], also known as rapamycin, and functions by inhibiting the [[mammalian target of rapamycin]] (mTOR), a key regulatory kinase involved in cell growth, proliferation, and survival. | |||
Umirolimus is | |||
== | == Mechanism of Action == | ||
== Side | Umirolimus exerts its effects by binding to the intracellular protein [[FK-binding protein 12]] (FKBP12). This complex then inhibits the mTOR pathway, which is crucial for [[T-cell]] activation and proliferation. By blocking this pathway, umirolimus effectively reduces the immune response, thereby decreasing the likelihood of organ rejection in transplant patients. | ||
As with | |||
== Clinical Applications == | |||
Umirolimus is primarily used in the context of [[organ transplantation]], particularly in [[kidney transplant]]s. Its ability to suppress the immune system makes it a valuable agent in preventing the body from attacking the transplanted organ. Additionally, umirolimus is being investigated for its potential use in treating certain [[cancers]], due to its antiproliferative properties. | |||
== Side Effects == | |||
As with other immunosuppressive agents, umirolimus can lead to a range of side effects. These may include increased susceptibility to [[infections]], due to the suppression of the immune system, as well as potential [[nephrotoxicity]] and [[hepatotoxicity]]. Patients on umirolimus therapy require careful monitoring to manage these risks. | |||
== Related Pages == | |||
* [[Sirolimus]] | * [[Sirolimus]] | ||
* [[ | * [[Immunosuppressive drug]] | ||
* [[ | * [[Organ transplantation]] | ||
* [[Mammalian target of rapamycin]] | * [[Mammalian target of rapamycin]] | ||
[[Category: | [[Category:Immunosuppressants]] | ||
[[Category: | [[Category:Transplantation medicine]] | ||
Latest revision as of 03:51, 13 February 2025
Umirolimus[edit]
Umirolimus is a pharmacological agent that belongs to the class of immunosuppressive drugs. It is primarily used in the field of medicine to prevent organ transplant rejection. Umirolimus is a derivative of sirolimus, also known as rapamycin, and functions by inhibiting the mammalian target of rapamycin (mTOR), a key regulatory kinase involved in cell growth, proliferation, and survival.
Mechanism of Action[edit]
Umirolimus exerts its effects by binding to the intracellular protein FK-binding protein 12 (FKBP12). This complex then inhibits the mTOR pathway, which is crucial for T-cell activation and proliferation. By blocking this pathway, umirolimus effectively reduces the immune response, thereby decreasing the likelihood of organ rejection in transplant patients.
Clinical Applications[edit]
Umirolimus is primarily used in the context of organ transplantation, particularly in kidney transplants. Its ability to suppress the immune system makes it a valuable agent in preventing the body from attacking the transplanted organ. Additionally, umirolimus is being investigated for its potential use in treating certain cancers, due to its antiproliferative properties.
Side Effects[edit]
As with other immunosuppressive agents, umirolimus can lead to a range of side effects. These may include increased susceptibility to infections, due to the suppression of the immune system, as well as potential nephrotoxicity and hepatotoxicity. Patients on umirolimus therapy require careful monitoring to manage these risks.
